Moleculin Biotech earnings were -$23.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest MBRX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$6.4M, up 242% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MBRX reported annual earnings of -$21.8M, with -26.9% growth.
What were Moleculin Biotech's earnings last quarter?
On MBRX's earnings call on Invalid Date, Moleculin Biotech (NASDAQ: MBRX) reported Q1 2025 earnings per share (EPS) of -$0.69, up 65.84% year over year. Total MBRX earnings for the quarter were -$6.44 million. In the same quarter last year, Moleculin Biotech's earnings per share (EPS) was -$2.02.
As of the last Moleculin Biotech earnings report, Moleculin Biotech is currently losing money. Moleculin Biotech's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$23.23 million, a 13.4% decrease year over year.
What was MBRX's earnings growth in the past year?
As of Moleculin Biotech's earnings date in Invalid Date, Moleculin Biotech's earnings has grown year over year. MBRX earnings in the past year totalled -$23.23 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.